The top 50 companies based on healthcare revenue continued the trend of spending more money on research and development in 2009 compared with prior years. The leading 50 pharma/biotech/generic players combined for a 2009 healthcare R&D expenditure of $104.63 billion. Additionally, total R&D expenditure as a percentage of the top 50 companies’ joint healthcare revenue in 2009 came in at around 16%, a figure in line within the number from the past few years and approaching the overall industry average of about 18%. The healthcare industry has been able to maintain its dedication to developing new medicines despite the many obstacles created by the economic downturn of recent years.
The following information is included for the top 50 pharmaceutical companies, which were determined based on their healthcare revenue generated during 2009:
- Each pipeline products’ chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer
- Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval
- Region of development includes the U.S., Europe, and Japan
- Select 2009 and 2008 financial data such as revenue, net income, earnings per share, and R&D expenditure